The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Long-Term Methotrexate Treatment in Corticosteroid-Dependent Asthma

Michael F. Mullarkey, MD; Joyce K. Lammert, MD; and Brent A. Blumenstein, PhD
[+] Article, Author, and Disclosure Information

Grant Support: In part by the American Lung Association of Washington State. Dr. Lammert is the H. Rowland Pearsall Fellow in Allergy and Clinical Immunology and is also funded by the American Lung Assocation of Washington State.

Requests for Reprints: Michael F. Mullarkey, MD: The Virginia Mason Clinic, 1100 Ninth Avenue, Seattle, WA 98111.

Current Author Addresses: Drs. Mullarkey and Lammert: The Virginia Mason Clinic, 1100 Ninth Avenue, Seattle, WA 98111.

Dr. Blumenstein: Fred Hutchinson Cancer Research Center, MP-557 1124 Columbia Street, Seattle, WA 98104.

©1990 American College of PhysiciansAmerican College of Physicians

Ann Intern Med. 1990;112(8):577-581. doi:10.7326/0003-4819-112-8-577
Text Size: A A A

Study Objective: To study the long-term efficacy and toxicity of low-dose methotrexate as corticosteroid-sparing adjunctive therapy in patients with corticosteroid-dependent bronchial asthma.

Design: A prospectively evaluated case series.

Patients: We studied 31 cushingoid asthmatics who needed daily prednisone and were found to be unable to reduce their prednisone dosage. These patients had used maximal daily doses of bronchodilator and inhaled corticosteroid and, on average, had used prednisone, 26.8 mg/d, for 4.7 years (range, 1 to 11 years). Of these 31 patients, 25 completed 18 to 28 months of methotrexate therapy.

Intervention: Patients were treated for at least 18 months with low-dose methotrexate (range, 15 to 50 mg/wk).

Results: The mean prednisone dose was reduced from 26.9 mg/d to 6.3 mg/d (P = 0.0001) in the 25 patients treated with long-term methotrexate: Fifteen patients discontinued the regular use of prednisone, 9 patients reduced prednisone use by more than 50%, and 1 patient failed to respond. The forced expiratory volume in 1 second (FEV1) improved from 1.7 L/s to 1.9 L/s (P = 0.0513), and subjective symptom scores for breathing ability, cough, wheeze, and frequency of nocturnal awakenings all improved. Adverse drug reactions were noted in 15 patients. These reactions were mild and did not lead to discontinuation of drug therapy.

Conclusion: Methotrexate is effective and safe when used as a long-term, corticosteroid-sparing agent in patients with severe bronchial asthma.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.